|Bid||7.99 x 4000|
|Ask||8.00 x 4000|
|Day's Range||7.98 - 8.00|
|52 Week Range||2.96 - 9.15|
|Beta (5Y Monthly)||2.60|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov. 03, 2021 - Nov. 08, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.60|
Supernus Pharmaceuticals (NASDAQ: SUPN) recently announced that it's acquiring Adamas Pharmaceuticals (NASDAQ: ADMS). In this Motley Fool Live video recorded on Oct. 13, Motley Fool contributors Keith Speights and Brian Orelli discuss why Supernus' planned acquisition of Adamas is a smart move.
NEW YORK, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NasdaqGM: ADMS) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of ADMS to Supernus Pharmaceuticals, Inc. for $8.10 in cash per share of ADMS owned. If you are an investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at
NEW YORK, NY / ACCESSWIRE / October 19, 2021 / The following statement is being issued by Levi & Korsinsky, LLP:Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies. (NASDAQ:ADMS)Agreement Announcement: October 11, 2021 Transaction Details:Upon the closing of the transaction, Supernus will acquire Adamas through a tender offer for $8.